CVS Health Elects Board at Annual Meeting

CVS Health ( (CVS) ) has shared an announcement.

At the CVS Health Corporation Annual Meeting of Stockholders held on May 15, 2025, all 13 nominees for the Board of Directors were elected for a one-year term. The stockholders approved the ratification of Ernst & Young LLP as the independent registered public accounting firm for 2025 and the advisory approval of executive compensation. However, a stockholder proposal to reduce the threshold for stockholder rights to act by written consent was not approved.

The most recent analyst rating on (CVS) stock is a Buy with a $72.00 price target. To see the full list of analyst forecasts on CVS Health stock, see the CVS Stock Forecast page.

Spark’s Take on CVS Stock

According to Spark, TipRanks’ AI Analyst, CVS is a Neutral.

CVS Health scores 67, reflecting strong financial performance with robust revenue growth and stable margins. The technical analysis shows mixed short-term signals but longer-term stability. The valuation is attractive with a reasonable P/E ratio and high dividend yield. Despite challenges such as high leverage and certain market segment difficulties, the company’s strategic initiatives and increased earnings guidance provide a positive outlook.

To see Spark’s full report on CVS stock, click here.

More about CVS Health

CVS Health Corporation operates in the healthcare industry, providing a wide range of services including pharmacy benefit management, retail and specialty pharmacy, and healthcare services. The company focuses on improving healthcare access and affordability, positioning itself as a leader in the integrated healthcare services market.

Average Trading Volume: 10,428,417

Technical Sentiment Signal: Sell

Current Market Cap: $79.42B

Learn more about CVS stock on TipRanks’ Stock Analysis page.